[ASSOCIATION OF CYCLIC CITRULLINATED PEPTIDE ANTIBODIES LEVEL WITH RHEUMATOID ARTHRITIS ACTIVITY BASED ON GLUCOCORTICOID RECEPTOR GENE BBL1 POLYMORPHISM].
The ambiguity of facts on connection between glucocorticoid receptor gene (GR) Bcl1 polymorphism in rheumatoid arthritis (RA) and its activity as well as lack of facts on its association with serological variants of the desease, makes ir reasonable to investigate its connections between cyclic citrullinated peptide antibodiss (ACCP) concentration and clinico-laboratorial parameters of RA (DAS 28 desease activity score, C-reactive protein concentration (CRP) and erythrocyte sedimentation rate (ESR) level based on GR gene Bcl1 polymorphism. Study involved 161 RA patients aged over 40 as well as 96 healthy individuals. Routine examination of RA diagnostics, anthropometric and molecular genetic methods were used in the research. Statistical analysis of the results was performed using SPSS-17 program. It has been proved that there is no significant difference in GR gene Bcl1 polymorphism distribution based on DAS 28 RA desease activity score, ACCP concentration and ESR level. However, we have found out that G/G genotype bearers have positive correlation relationship between ACCP titre and RA activity by laboratorial parameters (CRP, ESR),DAS 28 score and rheumatoid factor (RF) which has not been found in C/C and C/G genotype bearing patients. The above indicates the association of G/G genotype by GR gene Bcl1 polymorphism with clinico-laboratorial parameters of RA inflammatory activity. In course of the study we have identified the existance of correlation relationship between ACCP concentration and DAS 28 score of RA activity, CRP concentration and ESR level in individuals bearing G/G gene by GR gene Bcl11 polymorphism gene. The association between GR gene Bcl1 polymorphism and clinico-laboratorial parameters of RA inflammatory activity has not been found.
Sumy State University, Medical Institute, Department of Internal Medicine, Ukraine.
L
L
Prystupa
Sumy State University, Medical Institute, Department of Internal Medicine, Ukraine.
O
O
Savchenko
Sumy State University, Medical Institute, Department of Internal Medicine, Ukraine.
S
S
Koroza
D000328:Adult; D000368:Aged; D000075422:Anti-Citrullinated Protein Antibodies / Q000097:blood*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000235:genetics* / Q000276:immunology / Q000503:physiopathology; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000235:genetics / Q000276:immunology; D016022:Case-Control Studies; D015252:Deoxyribonucleases, Type II Site-Specific / Q000737:chemistry; D005260:Female; D015870:Gene Expression; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000097:blood / Q000276:immunology; D012150:Polymorphism, Restriction Fragment Length; D011965:Receptors, Glucocorticoid / Q000235:genetics* / Q000276:immunology; D012217:Rheumatoid Factor / Q000235:genetics / Q000276:immunology; D012720:Severity of Illness Index
D000075422:Anti-Citrullinated Protein Antibodies; D010456:Peptides, Cyclic; D011965:Receptors, Glucocorticoid; C487763:cyclic citrullinated peptide; D002097:C-Reactive Protein; D012217:Rheumatoid Factor; C041666:endodeoxyribonuclease BclI; D015252:Deoxyribonucleases, Type II Site-Specific